Role of Interferon-α and Clonally Expanded T Cells in the Immunotherapy of Chronic Myelogenous Leukemia

References

• Hasford J., Pfirrmann M., Hehlmann R., Allan N. C., Baccarani M., Kluin-Nelemans J. C., Alimena G., Steeg-mann J. L., Ansari H. A new prognostic score for patients with chronic myeloid leukemia treated with inter-feron alpha. J Natl Cancer Inst 1998; 90: 850–858
   PubMed Web of Science ®Google Scholar
• Ling P. D., Warren M. K., Vogal S. N. Antagonistic effect of interferon-beta on the inter-feron-gamma-induced expression of fa antigen in murine macrophages. J Immunol 1985; 135: 1857–1863
   PubMed Web of Science ®Google Scholar
• Siegal F. P., Kadowaki N., Shodell M., Fitzger-ald-Bacarsly P. A., Shah K., Ho S., Antonenko S., Liu Y. J. The nature of the principal type 1 inter-feron-producing cells in human blood. Science 1999; 284: 1835–1837
   PubMed Web of Science ®Google Scholar
• Cella M., Jarrossay D., Facchetti F., Alebardi O., Naka-jima H., Lavanzecchia A., Colonna M. Plasma-cytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type 1 interferon. Not Med 1999; 8: 919–923
   Google Scholar
• Ghanekar S., Zheng L., Logar A., Navratil J., Borowski L., Gupta P., Rinaldo C. Cytokine expression by human peripheral blood dendritic cells stimulated in vitro with HIV-1 and herpes simplex virus. J Immunol 1996; 157: 4028–4036
   PubMed Web of Science ®Google Scholar
• Tough D. F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947–1950
   PubMed Web of Science ®Google Scholar
• Marmont A., Horowitz M., Gale R., Sobocinski K., Ash R., van Bekkum D., Champlin R., Dicke K., Goldman J., Good R., Herzig R., Hong R., Masaoka T., Rimm A., Ringden O., Speck B., Weiner R., Borti M. T cell depletion of HLA identical transplants in leukemia. Blood 1991; 78: 2120–2130
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Mittermuller J., Clemm C., Holler E., Ledder-rose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1992; 76: 2462–2565
   Web of Science ®Google Scholar
• Smit W. M., Rijnbeek M., van Bergen C. A. M., Fibbe W. E., Willemze R., Falkenburg J. H. F. T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 1998; 95: 10152–10157
   PubMed Web of Science ®Google Scholar
• Coleman S., Fisher J., Hoy T., Burnett A. K., Lim S. H. Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia. Leukemia 1996; 10: 483–487
   PubMed Web of Science ®Google Scholar
• Legha S. S. The role of interferon-alpha in the treatment of metastatic melanoma. Semin Oncol 1997; 24(Suppl. 4)S24–31
   PubMedGoogle Scholar
• Weinstock-Guttman B., Ransohoff R. M., Kinkel R. P., Rudick R. A. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis [Review]. Ann. Neurol. 1995; 37: 7–15
   PubMed Web of Science ®Google Scholar
• Ellis T. M., McKenzie R. S., Simms P. E., Helfrich B. A., Fisher R. I. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol 1989; 143: 4282–4286
   PubMed Web of Science ®Google Scholar
• Meseri A., Delwail V., Brizard A., Lecron J. C., Pelletier D., Guilhot F., Tanzer J., Goube de Laforest P. Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukaemia treated with alpha-interferon. Br J Haematol 1993; 83: 218–222
   PubMed Web of Science ®Google Scholar
• Schmidt H., Kellermann-Kegreiss E., Steiert I., Walz J., Zinser R., Muller C. A. Differential regulation of human leukocyte antigen class I genes by interferon in vivo and in vitro. J Immunother 1993; 14: 169–174
   Web of Science ®Google Scholar
• Gutterman J. U. Cytokine therapeutics: lessons from interferon alpha. Proc Nutl Acad Sci USA 1994; 91: 1198–1205
   PubMed Web of Science ®Google Scholar
• Romagnani S. Induction of TH1 and TH2 responses: a key role for the “natural” immune response?. Immunology Today 1992; 13: 379–81
   PubMedGoogle Scholar
• Biron C. A. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol. 1997; 9: 24–34
   PubMed Web of Science ®Google Scholar
• Wenner C. A. M., Guler L., Macatonia S. E., O'Garra A., Murphy K. M. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 1996; 156: 1442–1447
   PubMed Web of Science ®Google Scholar
• McRae B. L., Semnani T., Hayes M. P., van Seventer G. A. The type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol 1998; 160: 4298–4304
   PubMed Web of Science ®Google Scholar
• Marrack P., Kappler J., Mitchell T. Type I interferons keep activated cells alive. J Exp Med 1999; 189: 521–529
   PubMed Web of Science ®Google Scholar
• Haque S. J., Williams B. R. Signal transduction in the interferon system [Review]. Semin Oncol 1998; 25: 14–22
   PubMed Web of Science ®Google Scholar
• Cho S. S., Bacon C. M., Sudarshan C., Rees R. C., Finbloom D., Pine R., O'Shea J. J. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 1996; 154: 4781–4789
   Google Scholar
• Mueller D. L., Seiffert S., Fang W., Behrens T. W. Differential regulation of bcl-2 and bcl-x by CD 3, CD28 and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long term survival of memory cells. J Immunol 1996; 156: 1764–1777
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on chronic myeloid leukemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Heimpel H., Hasford J., Kolb H. J., Pralle H., Hossfeld D. K., Quisser W., Loffler H., Hochhaus A., Heinze B., Georgii A., Bartram C. R., Griesshammer M., Bergmann H., Walther F., Fett W., Kleeberg U. R., Kabisch A. Randomized Comparison of inter-feron-a with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064–4077
   PubMed Web of Science ®Google Scholar
• Ohnishi K., Ohno R., Tomonaga M., Kamada N., Ono-zawa K., Kuramoto A., Dohy H., Mizoguchi H., Miya-waki S., Tsubaki K., Miura Y., Omine M., Kobayashi T., Naoe T., Ohshima T., Hirashima K., Ohtake S., Taka-hashi I., Morishima K., Naito K., Asou N., Tanimoto M., Sakurna A., Yamada K. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906–916
   PubMed Web of Science ®Google Scholar
• Silver R. T., Woolf S. H., Hehlmann R., Appelbaum F. R., Anderson J., Bennett C., Goldman J. M., Guihot F., Kantarjian H. M., Lichtin A. E., Talpaz M., Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the american society of hematology. Blood 1999; 94: 1517–1536
   PubMed Web of Science ®Google Scholar
• Sawyers C. Chronic myeloid leukemia. N Engl J Med. 1999; 340: 1330–1339
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Talpaz M., O'brien S., Kurzrock R., Gutterman J., Keating M. J., McCredie K. B., Freireich E. J. Chronic myelogenous leukemia-progress at the M. D. Anderson Cancer Center over the past two decades and future direction: First Emil Freireich Award Lecture. Clin Cancer Res 1997; 3: 2723–2733
   PubMed Web of Science ®Google Scholar
• Faderl S., Talpaz M., Estov S., Kantarjian H. M. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207–219
   PubMed Web of Science ®Google Scholar
• Allan N. C., Richards S. M., Shepherd P. C.A. on behalf of the UA Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia Results of the Medical Research Council randomized multi-centre trial of interferonanl for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Cortes J., Talpaz M., O'brien S., Rios M. B., Majlis A., Keating M., Freireich E. J., Kantarjian H. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol 1998; 16: 3279–3285
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Shaltrid M., Talpaz M., Kloetzer W. S., Gutterman J. U. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood 1987; 70: 1584–1588
   PubMed Web of Science ®Google Scholar
• Chronic Myeloid Leukemia Trialists Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89: 1616–1620
   PubMed Web of Science ®Google Scholar
• Yee K., Anglin P., Keating A. Molecular approaches to the detection and monitoring of chronic myeloid leukemia: therapy and practice. Blood Reviews 1999; 13: 105–126
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Smith T. L., O'Brien S., Beran M., Pierce S., Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 1995; 122: 254–261
   PubMed Web of Science ®Google Scholar
• Sacchi S., Kantarjian H., O'Brien S., Cohen P. R., Pierce S., Talpaz M. Immune-mediated and unusal complications during interferon alpha therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401–2407
   PubMed Web of Science ®Google Scholar
• Faderl S., Talpaz M., Estrov Z., Obrien S., Kurzrock R., Kantarjian H. M. The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341: 164–172
   PubMed Web of Science ®Google Scholar
• Hochhaus A., Reiter A., Skladny H., Reichert A., Saus-sele S., Hehlmann R. Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Rec Res Cancer Res 1998; 144: 36–45
   PubMedGoogle Scholar
• Muhlmann I., Thaler I., Hilbe W., Bechter O., Erdel M., Utermann G., Duba H. C. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome- positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Gene Chromosomes Cancer 1998; 21: 90–100
   PubMed Web of Science ®Google Scholar
• Dewald G. W., Wyatt W. A., Juneau A. L., Carlson R. O., Zinsmeister A. R., Jalal S. M., Spurbeck J. L., Silver R. T. Highly sensitive fluorescence in situ hybridization method to detect double BCWABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91: 3357–3365
   PubMed Web of Science ®Google Scholar
• Buno I., Wyatt W. A., Zinsmeister A. R., Dietz-Band J., Silver R. T., Dewald G. W. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 1998; 92: 2315–21
   PubMed Web of Science ®Google Scholar
• Lee M., Kantarjian H., Talpaz M. Association of the responsiveness to interferon (IFN) therapy with the BCR/ABL splicing patterns in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Blood 1992; 80: 210a, Suppl. (abstract)
   Google Scholar
• Shepherd P., Suffolk R., Halsey J., Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase or survival. Br J Haematol 1995; 89: 546–554
   PubMed Web of Science ®Google Scholar
• Lee M. S., Kantarjian H. M., Talpaz M., Freireich E. J., Deisseroth A., Trujillo J. M., Stass S. A. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome positive chronic myelogenous leukemia following interferon therapy. Blood 1992; 79: 1920–1923
   PubMed Web of Science ®Google Scholar
• Malinge M. C., Mahon E. X., Delfeau M. H., Daheron L., Kitzis A., Guilhot F., Tanzer J., Grandchamp B. Quantitative determination of the hybrid bcr-abl RNA in patients with chronic myelogenous leukemia under interferon therapy. Br J Haematol 1992; 82: 701–707
   PubMed Web of Science ®Google Scholar
• Hochhaus A., Lin F., Reiter Skladny H., van Rhee F., Shepherd P. C., Allan N. C., Hehlmann R., Goldman J. M., Cross N. C. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 1995; 91: 126–131
   PubMed Web of Science ®Google Scholar
• Gaiger A., Henn T., Horth E., Geissler K., Mitterbauer G., Maier-Dobersberger T., Greinix H., Mannhalter C., Haas O. A., Lechner K., Lion T. Increase of bcr-abl chimeric mRNA expression in tumour cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371–2378
   PubMed Web of Science ®Google Scholar
• Guilhot F., Lacotte-Thierry L. Interferon-a: mechanism of action in chronic myelogenous leukemia in chronic phase. Hematol Cell Ther 1998; 40: 237–239
   PubMedGoogle Scholar
• Giralt S., Kantarjian H., Talpaz M. The natural history of chronic myelogenous leukemia in the interferon era. Seminars in Hematology 1995; 32: 152–158
   PubMed Web of Science ®Google Scholar
• Santucci M. A., Soligo D., Pileri S., Zuffa E., Testoni N., Tura S. Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leukemia., & Lymphoma 1993; 1(Suppl. 1)113–118
   Web of Science ®Google Scholar
• Gordon M. Y., Marley S. B., Lewis J. L., Davidson R. J., Nguyen D. X., Grand F. H., Amos T. A., Goldman J. M. Treatment with interferon-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest 1998; 102: 710–715
   PubMed Web of Science ®Google Scholar
• Cornelissen J. J., Ploemacher R. E., Wognum B. W., Bors-boom A., Kluin-Nelemans H. C., Hagemeijer A., Lowen-berg B. An in vitro model for cytogenetic conversion in CML; interferon-α preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture. J Clin Invet 1998; 102: 976–983
   PubMed Web of Science ®Google Scholar
• Pendergast A. M., Quilliam L. A., Cripe L. D., Bassing C. H., Dai Z., Li N., Batzer A., Rabun K. M., Der C. J., Schlessinger J., Gishizky M. L. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175–85
   PubMed Web of Science ®Google Scholar
• Contente S., Kenyon K., Rimoldi D., Friedman R. M. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 1990; 249: 796–798
   PubMed Web of Science ®Google Scholar
• Noda M. Mechanisms of reversion [Review]. FASEB J 1993; 7: 834–840
   PubMed Web of Science ®Google Scholar
• Gutterman J. U. Cytokine therapeutics: lessons from interferon-α. Proc Natl Acad Sci USA 1994; 91: 1198–1205
   PubMed Web of Science ®Google Scholar
• Bhatia R., McCanhy J. B., Verfaillie C. M. Interferon-a restores normal PI intergrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996; 87: 3883–3891
   PubMed Web of Science ®Google Scholar
• Upadhyaya G., Guba S. C., Sih S. A., Feinberg A. P., Talpaz M., Kantarjian H. M., Deisseroth A. B., Emerson S. G. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 1991; 88: 2131–2136
   PubMed Web of Science ®Google Scholar
• Keating A. Investigation of bcr-abl transcription by Ph-positive chronic myeloid leukemia progenitors. Stem Cells. 1993; 3: 31–33
   Google Scholar
• Oka T., Sastry K. J., Nehete P., Schapiro S. J., Guo J. Q., Talpaz M., Arlinghaus R. B. Evidence for specific immune response against p210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia 1998; 12: 155–163
   PubMed Web of Science ®Google Scholar
• Jiang Y. Z., Kanfer E. J., Macdonald D., Cullis J. O., Goldman J. M., Barrett A. J. Graft-versus-leukemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant 1991; 8: 253–258
   PubMed Web of Science ®Google Scholar
• Datta A. R., Barrett A. J., Jiang Y. Z., Giumaraes A., Mav-roudis D. A., van Rhee F., Gordon A. A., Madrigal A. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994; 14: 517–524
   PubMed Web of Science ®Google Scholar
• Fujii S. -I., Shimizu K., Fujimoto K., Kiyokawa T., Shi-momura T., Taniguchi O., Kinoshita M., Kawano F. Analysis of a vaccinated chronic myelogenous leukemia patient with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res 1999; 90: 1117–1129
   PubMedGoogle Scholar
• Falkenburg J. H. F., Goselink H. M., van der Harst D., van Luxemburg-Heijs S. A. P., Kooy-Winkelaar Y. M. C., Faber L. M., de Kroon J., Brand A., Fibbe W. E., Willemze R., Goulmy E. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991; 174: 27–33
   PubMed Web of Science ®Google Scholar
• Tilkin A. F., Lubin R., Soussi T., Lazar V., Janin N., Mathieu M. C., Lefrere I., Carlu C., Roy M., Kayibanda M., Bellet O., Guillet J., Paillerets B. B. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 1995; 25: 1765–1769
   PubMed Web of Science ®Google Scholar
• Jung S., Schluesener H. Human T tymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991; 173: 273–276
   PubMed Web of Science ®Google Scholar
• McGahon A., Bissonnette R., Schmitt M., Cotter K. M., Green D. R., Cotter T. G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179–87
   PubMed Web of Science ®Google Scholar
• McWhirter J. R., Wang J. Y. An actin-binding function contributes to transformation by the bcr-abl onco-protein of Philadelphia chromosome-positive human leuke-mias. EMBO Journal 1993; 12: 1533–1546
   PubMed Web of Science ®Google Scholar
• Calabretta B., Venturelli D., Kaczmarek L., Narni F., Talpaz M., Anderson B., Beran M., Baserga R. Altered expression of G1-specific genes in human malignant myeloid cells. Proc Natl Acad Sci USA 1986; 83: 1495–1498
   PubMed Web of Science ®Google Scholar
• Lee S. W., Tomasetto C., Sager R. Positive selection of candidate tumor-suppressor genes by subtractive hybridization. Proc Natl Acad Sci USA 1991; 88: 1825–1829
   PubMed Web of Science ®Google Scholar
• Ten Bosch G. J., Toornvliet A. C., Friede T., Melief C. J., Leeksma O. C. Recognition of peptides corresponding to the joining region of p210 BCR-ABL protein by human T cells. Leukemia 1995; 9: 1344–1348
   PubMed Web of Science ®Google Scholar
• Pawelec G., Max H., Halder T., Bruserud O., Merl A., de Silva P., Kalbacher H. BCWABL leukemia onocogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low fequency in the repertoire of normal donors. Blood 1996; 88: 2118–2124
   PubMed Web of Science ®Google Scholar
• Chen W., Peace D. J., Rovira D. K., You S. G., Chewer M. A. T-cell immunity to the joining region of p210 BCR-ABL protein. Proc Natl Acad Sci USA 1992; 89: 1468–1472
   PubMed Web of Science ®Google Scholar
• Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S. Y., Sette A., Scheinberg D. A. Specific human cellular immunity to bcr-abl onocogene-derived peptides. Blood 1996; 87: 3587–3592
   PubMed Web of Science ®Google Scholar
• Mannering S. I., McKenzie J. L., Fearnley D. B., Hart D. N. J. HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysate. Blood 1997; 90: 290–297
   PubMed Web of Science ®Google Scholar
• Bocchia M., Wentworth P. A., Southwood S., Sidney J., McGraw K., Scheinberg D. A., Sette A. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680–2684
   PubMed Web of Science ®Google Scholar
• Dermine S., Molldrem J., Parker K. C., Jiang Y. Z., Mav-round D., Hensel N., Couriel D., Mahoney M., Coligan J. E., Barret A. J. Human CD8+ T lymphocytes recognize the fusion region of BCR-ABL hybrid protein present in chronic myelogenous leukemia. Blood 1995; 86: 158, Suppl
   Google Scholar
• Greco G., Fruci D., Accapezzato D., Barnaba V., Nisini R., Alimena G., Montefusco E., Vigneti E., Butler R., Tanigaki N., Tosi R. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996; 10: 693–699
   PubMed Web of Science ®Google Scholar
• Langlade-Demoyen P., Abastado J. P., Even J., Gourru G., Leblond V., Binet J. L., Kourilsky P. Cytotoxic T cell response against 210 kDA chimeric protein coded by the BCR-ABL fusion gene in chronic myeloid leukemia. Blood 1995; 86: 525, Suppl
   Google Scholar
• Yasukawa M., Ohminami H., Kaneko S., Yakushijin Y., Nishimura Y., Inokuchi K., Miyakuni T., Nakao S., Kishi K., Kubonishi I., Dan K., Fujita S. CD4+cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 1999; 92: 3355–3361
   Web of Science ®Google Scholar
• Ten Bosch G. J., Kessler J. H., Joosten A. M., Bres-Woemans A. A., Geluk A., Godthelp B. C., van Bergen J., Melief C. J., Leeksma O. C. A BCR-ABL onco-protein p210 b2a2 fusion sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood 1999; 94: 1038–1045
   PubMed Web of Science ®Google Scholar
• Jameson S. C., Carbone F. R., Bevan M. J. Clone specific T-cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J Exp Med 1994; 177: 1541–1550
   Web of Science ®Google Scholar
• Sloan-Lancaster J., Allen P. M. Altered peptide ligand-induced partial T-cell activation: Molecular mechanisms and roles in T-cell biology. Ann Rev Immunol 1996; 14: 1–27
   PubMed Web of Science ®Google Scholar
• Janeway C. A., Travers P. Immonobiology: The Immune System in Health and Disease. Current Biology, London 1994
   Google Scholar
• Shlomchik W. D., Emerson S. G. The immunobiology of T cell therapies for leukemias [Review]. Acta Haematol 1996; 96: 189–213
   PubMed Web of Science ®Google Scholar
• Paul W. E., Seder R. A. Lymphocyte responses and cytokines. Cell 1994; 76: 241–251
   PubMed Web of Science ®Google Scholar
• Rudd C. E., Janssen O., Cai Y. C., da Silva A. J., Raab M., Prasad K. V. Two-step TCR zeta/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyro-sine and lipid kinases. Immunology Today 1994; 15: 225–234
   PubMedGoogle Scholar
• Weiss A. T cell antigen receptor signal transduction: A tale of tails and cytoplasmic protein-tyrosine kinases [Review]. Cell 1993; 73: 209–212
   PubMed Web of Science ®Google Scholar
• Weiss A., Littman D. R. Signal transduction by lymphocyte antigen receptors [Review]. Cell 1994; 76: 263–274
   PubMed Web of Science ®Google Scholar
• Guinan E. C., Gribben J. G., Boussiotis V. A., Freeman G. J., Nadler L. M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity [Review]. Blood 1994; 84: 3261–3238
   PubMed Web of Science ®Google Scholar
• Willcox B. E., Gao G. F., Wyer J. R., Ladbury J. E., Bell J. I., Jakobsen B. K., van der Merwe P. A. TCR binding to peptide-MHC stabilizes a flexible recognition interface. Immunity 1999; 10: 357–365
   PubMed Web of Science ®Google Scholar
• Guinan E. C., Gribben J. G., Boussiotis V. A., Freeman G. J., Nadler L. M., Thompson C. B. The B7 and CD28 receptor families. [Review]. Immunology Today 1994; 15: 321–331
   PubMedGoogle Scholar
• Boussiotis V. A., Freeman G. J., Grey G., Gribben J., Nadler L. M. B7 but not intracellular adhesion molecule-l costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993; 178: 1753–1763
   PubMed Web of Science ®Google Scholar
• Boussiotis V. A., Gribben J., Freeman G. J., Nadler L. M. Blockade of the CD28 costimulatory pathway: A means to induce tolerance [Review]. Curr Opin Immunol 1994; 6: 797–807
   PubMed Web of Science ®Google Scholar
• Boussiotis V. A., Barber D. L., Nakarai T., Freeman G. J., Gribben J. G., Bernstein G. M., D'Andrea A. D., Ritz J., Nadler L. M. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 1994; 266: 1039–1042
   PubMed Web of Science ®Google Scholar
• Gimmi C. D., Freeman G. J., Gribben J., Grey G., Nadler L. M. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586–6590
   PubMed Web of Science ®Google Scholar
• Maini M. K., Casorati G., Dellabona P., Wack A., Beverley P. C. L. T-cell clonality in immune responses. Immunology Today 1999; 20: 262–266
   PubMedGoogle Scholar
• Piper H., Litwin S., Mehr R. Models for antigen receptor gene rearrangement. II. Multiple rearrangement in the TCR: Allelic exclusion or inclusion?. J Immunol 1999; 163: 1799–1808
   PubMed Web of Science ®Google Scholar
• Savage P. A., Boniface J. J., Davis M. M. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 1999; 10: 485–492
   PubMed Web of Science ®Google Scholar
• Posnett D. N., Sinha R., Kabak S., Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to “benign monoclonal gammapathy”. J Exp Med 1994; 179: 609–618
   PubMed Web of Science ®Google Scholar
• Wack A., Montagna D., Dellabona P., Casorati G. J. An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populations. J Immunol Methods 1996; 196: 181–192
   PubMed Web of Science ®Google Scholar
• Vavassori M., Maccario R., Moretta Comoli P., Wack A., Locatelli F., Lanzavecchia A., Maserati E., Dellabona P., Casorati G., Montagna D. Restricted TCR repertoire and long-term persistence of donor-derived antigen-experienced CD4+T cells in allogeneic bone marrow transplantation recipients. J Immunol 1996; 157: 5739–5747
   PubMed Web of Science ®Google Scholar
• Maryanski J. L., Jongeneel C. V., Bucher P., Casanova J. L., Walker P. R. Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: a high magnitude CD8 response is comprised of very few clones. Immunity 1996; 4: 47–55
   PubMed Web of Science ®Google Scholar
• Cochet M., Pannetier C., Regnault A., Darche S., Leclerc C., Kourilsky P. Molecular detection and in vivo analysis of the specific T cell response to a protein antigen. Eur J Immunol 1992; 22: 2639–2647
   PubMed Web of Science ®Google Scholar
• Mugnaini E. N., Egeland T., Syversen A. M., Spurkland A., Brinchmann J. E. Molecular analysis of the complementarity determining region 3 of the human T cell receptor beta chain. Establishment of a reference panel of CDR3 lengths from phytohaemagglutinin activated lymphocytes. J Immunol Methods 1999; 223: 207–216
   PubMed Web of Science ®Google Scholar
• Wack A., Cossarizza A., Heltai S., Barbieri D., D'Addato S., Fransceschi C., Dellabona P., Casorati G. Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets. Int Immunol 1998; 10: 1281–1288
   PubMed Web of Science ®Google Scholar
• Wedderbum L. R., Maini M. K., Patel A., Beverley P. C. L., Woo P. Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. Int Immunol 1999; 11: 535–543
   PubMed Web of Science ®Google Scholar
• Yamamoto K., Sakoda H., Nakajima T., Kato T., Okubo M., Dohi M., Mizushima Y., Ito K., Nishioka K. Accumulation of multiple T cell clonotypes in the synovial lesions of patients with rheumatoid arthritis revealed by a novel clonality analysis. Int Immunol 1992; 4: 1219–1223
   PubMed Web of Science ®Google Scholar
• Kurokawa M., Furukawa H., Yabe T., Matsui T., Toda M., Hamada C., Kasukawa R., Yamamoto K., Nishioka K., Kato T. Frequency of clonally expanded T cells evaluated by PCR from a single cell. J Immunol Methods 1999; 224: 203–208
   PubMed Web of Science ®Google Scholar
• Callan M. F., Tan L., Annels N., Ogg G. S., Wilson J. D., O'Callaghan C. A., Steven N., McMichael A. J., Rickinson A. B. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998; 187: 1395–1402
   PubMed Web of Science ®Google Scholar
• Callan M. F., Steven N., Krausa P., Wilson J. D., Moss P. A., Gillespie G. M., Bell J. I., Rickinson A. B., McMichael A. J. Large clonal expansions of CD8+T cells in acute infectious mononucleosis. Nat Med 1996; 2: 906–911
   PubMed Web of Science ®Google Scholar
• Maini M. K., Wedderburn L. R., Hall F. C., Wack A., Casorati G., Beverley P. C. A comparison of two techniques for the molecular tracking of specific T-cell responses; CD4+ human T-cell clones persist in a stable hierarchy but at a lower frequency than clones in the CD8+ population. Immunology. 1998; 94: 529–35
   PubMed Web of Science ®Google Scholar
• Algeciras A., Dockrell D. H., Lynch D. H., Paya C. V. CD4 regulates susceptibility to Fas ligand- and tumor necrosis factor-mediated apoptosis. J Exp Med 1998; 187: 711–20
   PubMed Web of Science ®Google Scholar
• Zimmerman C., Brduscha-Riem K., Blaser C., Zinker-nagel R. M., Pircher H. Visualization, characterization, and turnover of CD8+ memory T cells in virus-infected hosts. J Exp Med 1996; 183: 1367–75
   PubMed Web of Science ®Google Scholar
• Ehl S., Hoffmann-Rohrer U., Nagata S., Hengartner H., Zinkernagel R. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J Immunol 1996; 156: 2357–60
   PubMed Web of Science ®Google Scholar
• Singer G. G., Abbas A. K. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity. 1994; 1: 365–71
   PubMed Web of Science ®Google Scholar
• Sytwu H. K., Liblau R. S., McDevitt H. O. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity. 1996; 5: 17–30
   PubMed Web of Science ®Google Scholar
• Chambers C. A., Sullivan T. J., Allison J. P. Lym-phoproliferation in CTLA-Cdeficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 1997; 7: 885–95
   PubMed Web of Science ®Google Scholar
• Gullberg M., Smith K. A. Regulation of T cell autocrine growth. T4+ cells become refractory to interleukin 2. J Exp Med. 1986; 163: 270–84
   PubMed Web of Science ®Google Scholar
• Vella A. T., Dow S., Potter T. A., Kappler J., Marrack P. Cytokine induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 3810–3815
   PubMed Web of Science ®Google Scholar
• Zhang X., Sun S., Hwang I., Tough D. F., Sprent J. Potent and selective stimulation of memory-pheno-type CD8+ T cells in vivo by IL-15. Immunity 1998; 8: 591–599
   PubMed Web of Science ®Google Scholar
• Zeng W., Nakao S., Takamatsu H., Yachie A., Takami A., Kondo Y., Sugimori N., Yamazaki H., Miura Y., Shiobara S., Matsuda T. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine- dependent aplastic anemia. Blood 1999; 93: 3008–3016
   PubMed Web of Science ®Google Scholar
• Coleman S., Perera P., Fisher J., Hoy T., Burnett A. K., Lim S. H. Abnormal TCR V beta repertoire in patients with chronic myeloid leukaemia. Br J Haemarol 1995; 90: 358–363
   PubMed Web of Science ®Google Scholar
• Shimomura T., Fujii S. -I., Ezaki I., Osato M., Fujimoto K., Takatsuki K., Yamamoto K., Kawakita M. Characeterization of T-cell receptor β chain mRNA expression in IFN-α-responsive chronic myelogenous leukaemia patients. Br J Haematol 1999; 105: 173–180
   PubMed Web of Science ®Google Scholar
• Rezvany M. R., Jeddi-Tehrani M., Osterborg A., Kimby E., Wigzell H., Mellstedt H. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999; 94: 1063–1069
   PubMed Web of Science ®Google Scholar
• Trentin L., Imberti L., Zambello R., Sottini A., Raimondi R., Facco M., Cazzavillan S., Bonoldi E., Signorini S., Bacigalupo A., Semenzato G., Rodeghiero F., Primi D. Detection of identical T-cell clono-type expansions in both the donor and recipient after allo-geneic bone marrow transplantation. Br J Haematol. 1999; 106: 119–127
   PubMed Web of Science ®Google Scholar
• Claret E. J., Alyea E. P., Orsini E., Pickett C. C., Collins H., Wang Y., Neuberg D., Soiffer R. J., Ritz J. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymhpocyte infusion. J Clin Invet 1997; 4: 855–866
   Web of Science ®Google Scholar
• Cortes J., Fayad L., Kantarjian H., O'brien S., Lee M. -S., Talpaz M. Association of HLA phenotype and response to interferon-alpha in patients with chronic myel-ogeneous leukemia. Leukemia 1998; 12: 455–462
   PubMed Web of Science ®Google Scholar
• Mahon E. X., Faberes C., Pueyo S., Cony-Makhoul P., Salmi R., Boiron J. N., Marit G., Bilhou-Nabera C., Car-rere A., Montastruc M., Pigneux A., Bernard P. H., Reiffers J. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-α. Blond 1998; 92: 4059–4065
   PubMed Web of Science ®Google Scholar
• Choudhury A., Toubert A., Douay C., Charron D., Champlin R., Claxton D. MHC restriction and preferential TCR Vβ usage in anti-leukemic T lymphocytes elicited against autologous, CML-derived dendric cells from different CML patients. Blood 1997; 90(Suppl. 1)198
   Google Scholar
• Molldrem J. J., Lee P. P., Wang C., Champlin R. E., Davis M. M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999; 59: 2675–2681
   PubMed Web of Science ®Google Scholar
• Falkenburg J. H. F., Wafelman A. R., Joosten P., Smit W. M., van Bergen C. A. M., Bongaerts R., Lurvink E., van der Hoorn M., Kluck P., Landegent J. E., Kluin-Nele-mans H. C., Fibbe W. E., Willemze R. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201–1208
   PubMed Web of Science ®Google Scholar
• Fujii S. -I., Fujimoto K., Matsui K., Kawakita M., Takatsuki K. Induction of antitumor cytotoxic activity using CD34+ cord blood cell-derived and irradiated tumor cell-primed dendritic cells. Int J Hemarol 1998; 68: 169–182
   PubMed Web of Science ®Google Scholar
• Fujii S. -I., Fujimoto K., Shimizu K., Ezaki T., Kawano E., Takatsuki K., Kawakita M., Matsuno K. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogeneous leukemia patients. Cancer Res 1999; 59: 2150–2158
   PubMed Web of Science ®Google Scholar
• Fujii S. -I., Hamada H., Fujimoto K., Shimomura T., Kawakita M. Activated dendritic cells from bone marrow cells receiving cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing synegenic tumors. Blood 1999; 93: 1–9
   PubMedGoogle Scholar
• Nieda M., Nicol A., Kikuchi A., Kashiwase K., Taylor K., Suzuki K., Tadokoro K., Juji T. Dendritic cells stimulate the expansion of bcr-abl specific CD8+T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998; 91: 977–983
   PubMed Web of Science ®Google Scholar